Decee (gep) Peadiatric

Decee (gep) Peadiatric Uses, Dosage, Side Effects, Food Interaction and all others data.

Decee (gep) Peadiatric is an anthelmintic drug that does not resemble other antiparasitic compounds. It is a synthetic organic compound which is highly specific for several parasites and does not contain any toxic metallic elements. Decee (gep) Peadiatric continues to be the mainstay for treatment of patients with lymphatic filariasis and loiasis.

The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.

Decee (gep) Peadiatric
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Decee (gep) Peadiatric
Generic	Diethylcarbamazine
Diethylcarbamazine Other Names	Diethylcarbamazin, Diéthylcarbamazine, Diethylcarbamazine, Diethylcarbamazinum, Dietilcarbamazina
Type	Syrup
Formula	C₁₀H₂₁N₃O
Weight	Average: 199.2932 Monoisotopic: 199.168462309
Groups	Approved, Investigational, Vet approved
Therapeutic Class	Other Anti-protozoals
Manufacturer	Geno Pharmaceuticals Ltd
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Decee (gep) Peadiatric is used for Filariasis, Lymphatic filariasis, Pulmonary eosinophilia, Loiasis, Toxocariasis.

Decee (gep) Peadiatric is also used to associated treatment for these conditions: Filarial Infection, Onchocerciasis

How Decee (gep) Peadiatric works

The mechanism of action of diethylcarbamazine is thought to involve sensitizing the microfilariae to phagocytosis. One study showed that diethylcarbamazine's activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. It confirmed the important role of the arachidonic acid metabolic pathway in diethylcarbamazine's mechanism of action in vivo and showes that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1.

Dosage

Decee (gep) Peadiatric dosage

Inital: 1 mg/kg/day, may increase to 6 mg/kg/day over 3 days, then maintain for 3 wk. Prophylaxis of loiasis 300 mg/wk.

Side Effects

Fever, headache, vomiting, dizziness, drowsiness, nausea, chills.

Potentially Fatal: Severe hypersensitivity reactions may occur especially in the treatment of onchocerciasis where rare Mazzotti reaction characterised by rash, itching, headache, muscle and joint pains, tachycardia, postural hypotension may start within 2 hr of drug administration. Encephalitis and retinal haemorrhage.

Toxicity

Oral LD₅₀ in rat and mouse is 1400 mg/kg and 660 mg/kg, respectively.

Precaution

Patients with poor health.

Lactation: not known if excreted in breast milk.

Interaction

There are no known drug interactions and none well documented.

Elimination Route

Readily absorbed following oral administration.

Half Life

Approximately 8 hours.

Pregnancy & Breastfeeding use

Pregnancy Category- X. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.